With availability of Olumiant™ (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
TORONTO, Nov. 1, 2018 /CNW/ - "You would never know by looking at me," says Angela Vance, a Lilly employee, "that I have rheumatoid arthritis (RA)."
RA is a chronic autoimmune disease characterized by inflammation, pain, stiffness and progressive joint destruction, and affects roughly 300,000 Canadians.1 It is associated with higher rates of illness and premature death and, when RA is moderate to severe, the disease can reduce a life span by as much as a dozen years if untreated.2
"It's a horrible disease," she says. "It rears its head with sharp unexplained pain that won't fade, and a feeling of being wiped most of the time, like I've stayed up 36 hours straight."
"Rheumatoid arthritis can progress very quickly into a debilitating condition," said Edward Keystone, MD, FRCP(C), Professor of Medicine, University of Toronto. "Early diagnosis and referral to a rheumatologist for treatment is essential in order to get individuals' RA well controlled or in remission, quickly reduce pain, and avoid permanent damage to joints."
Despite current treatment options, many patients do not reach their therapeutic goals or sustained remission. Research shows that fewer than half of patients in clinical practice will sustain remission for more than 1 year.3 There remains an important need to provide additional treatments to improve overall patient care.4 The overall goals of treatment are to stop inflammation, relieve symptoms, prevent damage to joints and organs, improve physical function and overall well-being, and reduce long-term complications.5
Eli Lilly Canada Inc. is pleased to announce the availability of Olumiant™ (baricitinib), a once-daily, 2 mg oral tablet. Olumiant, in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). Olumiant may be used as monotherapy in cases of intolerance to MTX.6 7
"New oral options like Olumiant (also known as baricitinib) are key to helping rheumatologists like myself bring active rheumatoid arthritis under control—or even achieve remission—so patients can get back to enjoying their lives," says Dr. Janet Pope, Professor of Medicine, University of Western Ontario & Chair Division of Rheumatology St. Joseph's Health Care London.
"I'm proud of Lilly's longstanding research in autoimmunity, which has led to the approval of Olumiant so that people living with the devastating impact of RA, like me, have a new option," says Angela Vance from Lilly.
The research behind Olumiant:
Olumiant is believed to interfere with the activity of an enzyme called Janus Kinase (JAK). Normally JAK enzymes help turn on your immune system when you need it. The immune system then causes swelling and tenderness, which is called inflammation. Olumiant inhibits the action of JAK enzymes and thereby helps to reduce the swelling and tenderness in people with RA.6, 7
Olumiant was studied in patients with moderately to severely active RA who had an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (cDMARDs), in the RA-BUILD study, and in patients who had an inadequate response or intolerance to one or more biologic therapies (including Tumor Necrosis Factor (TNF) inhibitor) despite ongoing treatment with cDMARDs, in the RA-BEACON study.6
Results from both the RA-BUILD study and the RA-BEACON study demonstrated that patients treated with Olumiant 2 mg once daily had statistically significantly higher ACR20, ACR50 and ACR70 response rates at 12 weeks compared to placebo-treated patients (ACR = American College of Rheumatology score; ACR20/50/70 represents at least a 20/50/70 percent improvement across selected measures of disease activity). In both studies, higher ACR20 response rates were observed as early as one week with Olumiant 2 mg versus placebo. Patients treated with Olumiant 2 mg also had higher rates of clinical remission and achieved a DAS28 – hsCRP – a measure of RA disease activity – below 2.6 (indicating disease remission) versus placebo-treated patients at Week 12.6 In addition, in both studies, compared to placebo, patients treated with Olumiant 2 mg demonstrated greater improvement from baseline in the physical component summary (PCS) score and the physical function, bodily pain, vitality, and general health domains at Week 12.6
"For many people living with arthritis, the act of opening a medicine bottle or picking up a tablet can be extremely difficult, and Lilly designed the Olumiant tablet, bottle and cap with this in mind," says Bruce Watson, Arthritis Society Director of Business and Foundation Development. "We are pleased to give Olumiant our Ease of Use designation, which recognizes products that are designed to make life easier for people with arthritis."
"Olumiant is an innovative oral medicine that represents an evolution in the treatment of RA," said Lisa Matar, President and General Manager of Lilly Canada. "At Lilly, we focus on the whole person, so the patient's voice is front and centre. We are dedicated to ongoing collaboration with the community to identify solutions that help people with RA thrive."
Lilly received a Notice of Compliance for Olumiant from Health Canada on August 17, 2018.
Notes to Editors:
About Olumiant™
Olumiant™ (baricitinib), a once-daily, 2 mg oral tablet, provides a new approved treatment option for adult patients living with RA in Canada.6 Olumiant, in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). Olumiant may be used as monotherapy in cases of intolerance to MTX.6
Olumiant is believed to interfere with the activity of JAK enzymes. The four known JAK enzymes include: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases. Normally JAK enzymes help turn on your immune system when you need it. The immune system then causes swelling and tenderness, which is called inflammation. Olumiant inhibits the action of JAK enzymes and thereby helps to reduce the swelling and tenderness in people with RA.6, 7 Olumiant is approved in more than 50 countries.
For more information about Olumiant refer to the product monograph.
About Rheumatoid Arthritis (RA)
As a chronic autoimmune disease characterized by inflammation, pain, stiffness and progressive joint destruction, RA is a significant population health concern, affecting 300,000 Canadians, and is associated with higher rates of illness and death.3
RA affects women two to three times more often than men, and while the disease can occur at any age, its onset is most common between the ages of 40 and 60. Although its cause is still unknown, RA is believed to be the result of a malfunctioning immune system.3
About Eli Lilly Canada Inc.
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.
Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.
SOURCE Eli Lilly Canada
Partnering for rehabilitation success: Mackenzie Health and SE Health
RICHMOND HILL, ON, Nov. 1, 2018 /CNW/ - Today, Mackenzie Health renewed its rehabilitation services partnership with SE Health. Under the new six-year agreement, SE Health will provide experienced rehabilitation staff for 17 inpatient and outpatient programs at Mackenzie Richmond Hill Hospital and its community-based locations, as well as the future Mackenzie Vaughan Hospital, scheduled to open in late 2020.
Rehabilitation services such as physiotherapy and occupational therapy play a key role in helping patients achieve wellness in their recovery. In addition to supporting patients who live with chronic disease, a high-functioning rehabilitation program helps to alleviate pressures on the health care system by helping patients receive the care they need both within and outside of a hospital setting.
Since 2013, Mackenzie Health and SE Health have partnered on an innovative service delivery model that has increased patient participation in rehabilitation programs by 30 per cent. Both organizations share a passion for excellence, with a consistent focus on best practices, healthy outcomes and patient satisfaction.
"We look forward to continuing our partnership with SE Health for another six years, as rehabilitation truly makes a meaningful impact in the wellness and recovery of our patients. As we look to the future, we see great potential for this collaboration across all Mackenzie Health sites," says Altaf Stationwala, President and CEO, Mackenzie Health.
"SE Health is honoured to continue our successful partnership with Mackenzie Health to create a world-class rehab experience and serve the growing communities of York Region. By bringing the hospital and community sectors together, we can find new ways to deliver care and support people and families in their health journey," says Shirlee Sharkey, CEO, SE Health.
About Mackenzie Health
Mackenzie Health is a dynamic regional health care provider which includes the existing Mackenzie Richmond Hill Hospital and the future Mackenzie Vaughan Hospital, as well as a comprehensive network of community-based services. In March 2017, the organization received its second consecutive award of Accreditation with Exemplary Standing from Accreditation Canada for its commitment to safety and quality patient care. This is the highest rating a Canadian health care provider can receive. Guided by a vision to create a world-class health experience, Mackenzie Health has an unrelenting focus on the patient and is dedicated to patient needs now and in the future. With over 500,000 residents in Southwest York Region, Mackenzie Health is proud to serve one of the fastest growing and most diverse communities in Canada. For more information, please visit mackenziehealth.ca.
About SE Health
SE Health is a not-for-profit social enterprise applying knowledge, vision and drive to forever impact how people live and age at home, today and into the future. With Canadian roots and 110 years of expertise, the organization brings quality excellence and innovation to home care, seniors' lifestyle, and family caregiving. Through its team of 9,000 Leaders of Impact, SE Health delivers 20,000 care exchanges daily, totaling 50 million in the last decade alone. Visit us online at sehc.com.
SOURCE SE Health
Click here for the Infographic-Peanuts a More Affordable Option for Controlling Diabetes
New Study Shows Peanuts Match Almonds for Controlling Diabetes
Low-cost Peanuts Deliver Numerous Superfood Health Benefits
Albany, Ga. (November 1, 2018) – If you thought almonds were healthier than peanuts, think again. A study published in the journal Nutrients in October 2018 found that peanuts are just as good as almonds for lowering blood glucose levels in diabetic patients.
"Research has shown that eating nuts is beneficial for type 2 diabetes,” says Dr. Samara Sterling, director of research for The Peanut Institute. “This new study highlights that people can choose peanuts as a low-cost option to get the same benefits that they would from a more expensive nut like almonds. In fact, the American Diabetes Association considers peanuts a superfood.”
The recent study sought to compare the effects of either peanut or almond consumption on health in patients diagnosed with type 2 diabetes. Twenty-five participants were fed a low-carbohydrate diet for 12 weeks and were placed in one of two groups: the Almond group or the Peanut group.
All participants were instructed to consume approximately two servings of peanuts or almonds each day. By the end of the 12 weeks, they all showed significant improvement in various measures for diabetes. However, the authors of the study found that almonds were no better than peanuts for improving glucose levels. In fact, peanut consumption improved both fasting blood glucose and postprandial glucose (glucose levels tested two hours after a meal). By the end of the study, there was also no difference in hemoglobin A1c levels (a marker of long-term glucose control) between the Peanut and Almond groups.
The authors noted that, while nuts are routinely recommended for controlling type 2 diabetes, it is not always possible for many patients to consume tree nuts due to their high cost.
Peanuts are a low-cost option that can help to lower blood glucose if consumed daily as part of a balanced diet. That is good news for the 29 million people in the United States suffering from type 2 diabetes. With the rising cost of medications to control this condition, it is reassuring to know that eating healthy does not have to be costly too.
In fact, eating peanuts may even contribute to reducing insulin needs over time, which is an added benefit. Peanuts have a low glycemic index of 14, which prevents spikes in blood sugar and in turn reduces insulin needs. A previous study demonstrated that when peanuts or peanut butter are included in a high glycemic load meal, they keep blood sugar stabilized so that it does not rise too quickly. In addition, a 2014 study found that daily consumption of peanuts enriched the American Diabetes Association meal plan and improved blood lipids as well as vitamin E, niacin and magnesium levels of participants.
Link to the study: https://www.ncbi.nlm.nih.gov/pubmed/30360498
Other references
Arya, S.S., A.R. Salve, and S. Chauhan, Peanuts as functional food: a review. J Food Sci Technol, 2016. 53(1): p. 31-41.
Johnston, C.A., et al., Weight loss in overweight Mexican American children: a randomized, controlled trial. Pediatrics, 2007. 120(6): p. e1450-7.
Wien, M., K. Oda, and J. Sabaté, A randomized controlled trial to evaluate the effect of incorporating peanuts into an American Diabetes Association meal plan on the nutrient profile of the total diet and cardiometabolic parameters of adults with type 2 diabetes.Nutrition journal, 2014. 13: p. 10-10.
Dr. Samara Sterling is a Nutrition Scientist with expertise in the use of plant-based nutrition for the prevention and treatment of chronic diseases. She currently serves as the Research Director for The Peanut Institute and has also worked as a nutrition consultant for various community-based nutrition projects. She holds a bachelor’s degree from Stony Brook University, a master’s degree from Andrews University and a Ph.D. from the University of Alabama at Birmingham.
Pro-Cannabis Steamroller Impacts Canada, U.S. Elections and Stock Market
With Canada’s recent legalization of cannabis, pro-cannabis forces are increasingly optimistic about their future in the United States.
“Those in favor of legalization of cannabis have not yet won the war in America, but they are winning many of the battles,” says attorney Sarah Lee Gossett Parrish (www.sarahleegossettparrish.com), who handles many marijuana-related issues for clients. But the war obviously has not been won.
“Unfortunately, the different positions of the pro-cannabis states and the federal government are causing a lot of issues that still must be resolved. In states where it is legal, cannabis businesses still need to be protected from federal prosecution. Also, federal regulations need to be relaxed so legal cannabis enterprises can obtain banking services.”
New fights continue to emerge and the next one will be the U.S. elections set for November 6.
“Several states are beginning to look like dominoes ready to fall,” Parrish says.
“The movement toward national legalization remains an elusive objective for cannabis supporters, but momentum is shifting from ‘if it will happen’ to ‘when it will happen.’”
- Michigan, North Dakota, Utah and Missouri are all considering measures to loosen marijuana laws. If all four states vote for legalization, responsible adult usage of marijuana would be legal in 11 states and the District of Columbia, and marijuana would be legal for medical use in 33 states.
- Six states – Florida, Connecticut, New Hampshire, New York, Michigan, and Illinois – all feature gubernatorial races that feature pro-cannabis Democratic candidates running against anti-cannabis Republicans.
- The United States government remains locked in its position that cannabis is a Schedule 1 narcotic similar to heroin and opium. With America’s focus on illegal immigration and President Trump’s indication that he will build the wall for which he campaigned, suddenly eyes are starting to turn to America’s northern border where the longest international boundary between two countries is located.
Border officials have already stated that they are taking a zero-tolerance approach toward anyone who is caught trying to bring cannabis or cannabis products into the United States from any country, including Canada. However, the Canadian border is much more easily crossed illegally than the border with Mexico.
The Canadian cannabis decision is already being felt on Wall Street. Only a few days after Canadians legalized cannabis, Aurora Cannabis, one of the largest Canadian marijuana producers, went public on the New York Stock Exchange. When Aurora's shares started trading, the company joined a select list of cannabis producers that are listing on U.S.-based exchanges.
Aurora already trades on the Toronto Stock Exchange under the ticker ACB. The Edmonton-based cultivator grows cannabis for both the adult-use and medicinal markets. On Aug. 15, the beverage giant Constellation Brands announced it was upping its stake to $4 billion in an Aurora rival, Canopy Growth.
“There are significant challenges ahead for those who champion the legalization of cannabis,” says Parrish. “However, there are positive developments that signal many more states will join the green tide to decriminalize cannabis possession. Recreational pot may be a bridge too far for some states, but overall, the pro-cannabis forces are racking up some impressive wins.”
About Sarah Lee Gossett Parrish
Sarah Lee Gossett Parrish (www.sarahleegossettparrish.com) is an attorney who maintains a civil litigation practice and is admitted to practice in Oklahoma and in Texas. She also is admitted to practice before several District Courts in Oklahoma; the United States Court of Appeals for the Tenth Circuit and the United States Supreme Court. Ms. Parrish received her B.A. in Letters from the University of Oklahoma, Phi Beta Kappa, Summa Cum Laude. She also served as Chairman of the Governor's Commission on the Status of Women for the State of Oklahoma and was instrumental in starting the Oklahoma Women's Hall of Fame. She received her Juris Doctorate from the University of Oklahoma College of Law. Her legal thriller, Guilt of Innocence, p
Struggling to Reach Your Health Goals? The Importance of a Personalized Fitness Plan
When you’re working toward a specific health goal, there are so many factors to consider. Quality of rest, the water intake and stress factors are important. It’s also best to remember the average intake of calories in addition to the exercises you’re doing. Since there is a laundry list of factors you have to consider when you’re working on achieving health goals, it’s a good idea to implement a personalized fitness plan. If you’re feeling unsure of the concept, consider the following four reasons why a personalized fitness plan is a great approach to take.
Strength Training is Essential
Most fitness professionals will encourage a well-rounded approach to your exercises. This means that they will probably suggest some sort of strength-training regimen. Many people skip the weights in order to run on the treadmill for 45 minutes. When you’re getting a personalized plan, you’ll be able to tailor the workouts to your needs. You’ll also be able to get rid of any intimidation regarding weight-lifting because it has to get done.
Factor in the Injuries
The worst thing you could do is overwork an area of your body in the wrong way. If you’ve had a sprained wrist, it’s not a great idea to start lifting weights. You don’t want to put unnecessary pressure on your wrists. Personalized fitness plans factor in components like injuries that can prevent you from achieving a specific goal when they’re not addressed.
Find Enjoyable Activities
When a fitness plan is personalized, there’s a chance for you to talk about the workouts you love and prefer. If you enjoy group cycling, it’s wise to communicate that desire. If you associate a workout with death, that won’t motivate you to stick with it. When you’re able to talk through your concerns with a fitness professional, this will help shift your experience.
Talk to a Professional
Just like you’re a professional who’s worked in your field for a certain number of years, there are fitness professionals, like those at Plan 7 Coaching, who have done the same thing. Too often, people make the unfortunate mistake of believing that they know it all, and they can handle the nuances of a fitness journey on their own. Allow professionals into your space to help you get from point A to point B in an efficient manner.
As you work toward your specific health goals, it’s important to remain focused and committed. As you’re able to be intentional about your journey, you should be able to results over a period of time. No matter what, commit to the process and it will reward you.
Loss Is A Four-Letter Word: Provides The Tools To Help Anyone Who's Lost A Spouse Find Their Own Healing Journey Forward
"Carole Brody Fleet is forthright in dealing with many of the difficult issues surrounding widowhood, demonstrating that you do not have to live in your past. It's not an either-or situation. She teaches the important lesson that you can incorporate your previous life into a new life.”
— Jane Brody, personal health columnist, The New York Times
Deerfield Beach, FL, October 31, 2018 — No widow or widower look exactly the same. No widowhood looks exactly the same. Therefore, no healing journey or timeline is an identical experience. The word "loss” contains only four letters, but its size belies the amount of fear it produces at even its mere mention. Even more terrifying and enormous is the reality of loss–specifically, the loss of a spouse.
Widowhood has the capacity to keep those affected from moving forward into a new and fulfilling life. The loss of a spouse is frightening. The call for relatable and actionable direction and advice remains a very real need for the widowed community, and that is just what Loss is a Four-Letter Word offers. Award-winning author Carole Brody Fleet personally experienced the pain and grief as a young widow and mother; leaving her and her 9-year-old daughter alone. Loss is a Four-Letter Word shows readers a way out, a way to move forward– not "get over”–their most profound loss in positive ways. Fleet combines no-nonsense, direct advice with specific, boot-camp style "assignments” that are framed with compassion and humor to help them through a most challenging life-journey.
A short sample of the Bereavement Boot Camp Lessons:
• Lesson One: I'm Still Here
• Lesson Two: "My Healing Journey Is Mine”
• Lesson Three: Stop Putting Off Proactivity
• Lesson Four: "I Turn to… Who?”
• Lesson Five: Put Your Tits on Your Back
• Lesson Six: Get Up, Get Moving… Get Out!
• Lesson Seven: It's Your Turn
• Lesson Eight: Past, Present, and Future: You Can Have All Three
Loss is a Four-Letter Word gives readers help without reproach, education without lecture, and support without judgment, condition, or negative opinion. All of which provides a necessary light during such devastating times. Fleet tells them, "Because while our spouses may have departed this earth, we are still here. And we matter too.”
About the Author:
Carole Brody Fleet is the award-winning author of When Bad Things Happen to Good Women, Happily EVEN After, and Widows Wear Stilettos. Widely recognized as America's go-to expert on life adversity and grief recovery, Ms. Fleet is also a three-time contributor to the iconic Chicken Soup for the Soul book series, as well as a regular contributor to The Huffington Post and to ThirdAge.com. Ms. Fleet is also a popular motivational speaker and with her inimitable message of "What Now and What Next?” Ms. Fleet offers practical, emotional, and even humorous guidance to the millions who have experienced any kind of loss or challenge in their lives.
Loss Is A Four-Letter Word: A Bereavement Boot Camp for the Widowed
By Carole Brody Fleet
ISBN: 9780757321214
September 2018
$15.95
Available wherever books are sold or to order directly from the publisher, contact:
(800) 441-5569 or www.hcibooks.com
###
Suggested Interview Questions:
1. Where did the title of the book come from?
2. How does Loss is a Four-Letter Word differ from all of the other "grief” books?
3. What inspired you to write Loss is a Four-Letter Word?
4. What inspired you to begin writing in the loss / grief recovery genre in the first place – after all, these are not the happiest subjects in the world.
5. This is the first time that any of your writings have included a discussion on spirituality in connection with grief recovery. Why did you decide to include a chapter on spirituality when you have shied away from it in the past?
6. What are some of the lessons and experiences that you felt were especially necessary to communicate in the book?
7. What are some of the most common problems and challenges that face the widowed and what are the best ways to move past those challenges?
8. You have received hundreds of thousands of letters over the years. If you had to pick just one thing, what would be the one most common problem that people write to you about?
9. One of your favorite subjects concerns some of the things that people say when trying to help or otherwise comfort someone coping with loss. Even though most likely mean no harm, what are some of the dumbest things that you know people have said?
10. What are some of the first steps to take at the beginning of a healing journey?
Reviews:
Karen Noé, author, We Consciousness: 33 Profound Truths for Inner and Outer Peace and Your Life After Their Death: A Medium's Guide to Healing After a Loss: "Carole Brody Fleet has done it again! In Loss is a Four Letter Word, she offers practical, straightforward advice on how to move forward on a positive path after losing a loved one. I've had Carole as a guest on the "Angel Quest” radio show a number of times because of how much she has benefited my listeners with her knowledge. If it sounds like I am impressed with her, it's because I am. I love this book, and I love Carole!”
Lisa Lockwood, crime analyst, author, police and military veteran: "What I love and appreciate is Carole Brody Fleet's firsthand knowledge and approach on the most taboo topic in society. Having gone through personal loss, I always learn something about how to approach the topic with empathy and how to permit others to comfort me in the worst of times.”
Stacey Gualandi, Emmy award-winning journalist: "Carole Brody Fleet has faced painful challenges and loss with courage and resilience. Through her own personal healing, we can all learn from and be inspired by her. I have a four-letter word for Carole: HERO.”
Kristin Higson-Hughes, Senior Features Editor, Women's World Magazine: "Just as there is no timetable to grief, there certainly is no checklist on how to recover strength and joy after suffering a loss. Here you will find authentic, candid, trustworthy, and--perhaps most pertinent of all--pragmatic advice promising that although the landscape of life may forever be changed, the future can still hold purpose, beauty, and magic. With a signature style all her own, Carole Brody Fleet "trains" you to find yourself again (hint: there's no wrong path, but some are healthier for your soul!). Together, you will navigate everything from social media to financial matters to the possibility of finding love again. Sure, it can feel impossible to do, and even more so to find answers, but sign up, dear recruit, and discover this book's wit and wisdom, and its author's enormous-as-the-universe heart!"
Kim Iversen, nationally syndicated radio show host: "Carole is an angel, not just an expert. Many of us have no clue what to say to a loved one going through tremendous loss. We sit by and watch helplessly as they struggle with their 'new normal'. Carole's book is a must read; not just for widows, but for those of us who love a widow as well. As a relationship radio talk show host, I have always had words to comfort and guide someone through every type of heartache-----every heartache except the death of a spouse. This type of loss leaves many of us speechless. Finally, someone who knows what to say when the rest of us do not."
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
ProMIS' proprietary discovery platform generates additional potential opportunities for pharma partnering
TORONTO and CAMBRIDGE, MA, Oct. 31, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the identification of novel targets on misfolded, pathological forms of tau. The development of antibody therapeutics that selectively block these toxic forms of tau constitutes an exciting approach to treating Alzheimer's and other neurodegenerative diseases.
"Using our unique discovery platform, we were able to identify several novel targets displayed on misfolded forms of tau. We now look forward to generating antibody candidates that selectively block these toxic forms of tau." stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. "In addition to PMN310, our lead therapeutic candidate that selectively targets the toxic oligomers of amyloid beta, a root cause of Alzheimer's disease, the development of antibodies selective for toxic forms of tau affords ProMIS a 'one-two punch' in our armamentarium to fight Alzheimer's disease."
The tau protein plays a key role in stabilizing the microtubules in central nervous system neurons. The development of misfolded forms of tau leads to toxicity and abnormal neuronal function seen in Alzheimer's disease, frontotemporal dementia and other tauopathies such as repetitive head injury (chronic traumatic encephalopathy, or CTE).
Commenting on these results, Dr. Elliot Goldstein, ProMIS President and CEO stated: "ProMIS' proprietary discovery platform continues to show outstanding ability and efficiency to predict novel therapeutic targets and generate highly selective therapeutic antibodies for multiple neurodegenerative diseases. Having previously announced encouraging antibody candidates for ALS (targeting TDP43) and Parkinson's disease (targeting alpha-synuclein) and now novel targets on tau protein, we have additional exciting opportunities for high value pharma partnering across a broad spectrum of neurodegenerative diseases in 2019."
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences, please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
The Mummy Tuck: Procedure Aims to Restore Postpartum Body Confidence
TORONTO, Oct. 31, 2018 /CNW/ - Nearly two years ago, Kelly, then 46, realized diet and exercise alone was not going to get her back to her pre-baby body. The mother of two children, currently aged eight and eleven, hadn't worn a pair of jeans in nearly ten years and decided to explore her options. Now, the 48-year-old happily wears jeans, and even a bikini, with confidence. The reason – the Mummy Tuck.
Post-pregnancy, there are many new-moms who can bounce back to their pre-baby bodies through exercise and eating healthy. However, some women can't get rid of the belly pooch, no matter how many SoulCycle or Pilates classes they push through. Anna, a 46-year-old mother of two children aged seven and five, was hesitant about the Mummy Tuck at first, but after doing some Internet research she knew it was the right path forward. "I initially thought 'no way', but after having the kids I was never the same." Anna says, "I lost all of this weight and the extra skin bothered me so much. I started looking online at before and afters and thought 'that's pretty amazing'."
Both Kelly and Anna came across Power Plastic Surgery, an all-female private practice, through some Google searches. They both knew they wanted a female doctor, as Kelly says, "because who knows a woman's body better than a woman." Dr. Stephanie Power works with her Mummy Tuck patients to restore their body confidence post-pregnancy.
The tummy isn't the only area that adjusts during pregnancy. A Mommy Makeover, which addresses both the abdomen and breasts, are becoming increasingly popular. "Mommy makeover -- cosmetic breast surgery and tummy tuck -- is one of the most common procedures in my practice," says Dr. Power. "While pregnancy may be possible after a tummy tuck, it is recommended to wait until finished having children before undergoing this surgery. The results of a tummy tuck would be compromised otherwise. I make similar recommendations to women considering cosmetic breast surgery if planning a pregnancy in the near future."
"I wasn't overweight, I just had this excess of skin," says Kelly. "There was nothing I could do to get rid of it. I felt guilty going out there and spending money on this instead of my family or taking a vacation. Dr. Power's reassurance that there's absolutely nothing else I could do to get rid of the skin, and that it will make a huge difference really played a huge role in adjusting my thinking – that I wasn't dieting enough or working out enough. I just couldn't change it and it was nice to have that reassurance."
Referred to in the medical field as an Abdominoplasty, the procedure improves abdominal contour, corrects excess abdominal skin and tissue and repairs the rectus diastasis (those "six pack" muscles). Basically, it helps to vanish love handles, muffin tops and create that coveted hourglass shape.
Anna was initially worried that a visit to the plastic surgeon's office would be a frustrating experience, with the doctor pointing out all her flaws. "Dr. Power had a very nice approach. After watching TV shows you think you are going to go in and the plastic surgeon is going to draw on you and tell you everything that's wrong. She didn't do that at all. Often doctors have an arrogance and she was like to talking to a regular person," Anna explains.
Post surgery, the patient remains overnight until the following morning for observation and pain control. Anna had her procedure back in June and notes the recovery is similar to when she had a C-Section. She didn't experience any complications.
When asked if they would do the procedure again should they have to, both didn't hesitate in responding, "yes". Anna adds, "It couldn't have been any better than it was, mostly because of Dr. Power, she knows her stuff. I felt really confident with her and knew things weren't going to go sideways."
The Mummy Tuck is performed under general anesthetic. Patients are generally able to return to work within 1 – 2 weeks but should refrain from heavy lifting for 4 – 6 weeks. For more information, or to request an interview with Dr. Power, please contact Gillian DiCesare, gd@overcat.com.
ABOUT POWER PLASTIC SURGERY
Opened in 2013 by Dr. Stephanie Power, Power Plastic Surgery is an all-female practice located in Yorkville, Toronto. Performing both cosmetic and reconstructive procedures, the practice provides patients with personalized care in state of the art operating rooms. Dr. Power personally performs each consultation and surgery and maintains open communication with each patient following their procedures to address any questions they may have. For more information about Power Plastic Surgery, please visit http://www.powerplasticsurgery.com/.
SOURCE Power Plastic Surgery
BlockStrain: Taking The Marijuana Industry Out Of The Shadows And Safely Into The Future
New York, NY, October 30, 2018 — The world has seen many changes developing around the use of marijuana over the past decade. With the majority of states in the US now legalizing some aspect of cannabis, Canada is about to become the first G7 country to fully legalize the drug for medical and recreational purposes. While there is a great deal of interest from business giants, such as, Coca Cola, Constellation Brands and even Walmart, to stake their claim in this exciting and evolving industry, states such as Colorado and California continue to run into the same problem—how to bring integrity and quality assurance to an industry born in the shadows.
While the Canadian government has regulations on legal marijuana, these regulations are not stopping tainted products getting into the marketplace. There is currently no system in place to monitor and track the product to ensure it is safe. That is, until now.
One innovative technology company based in Vancouver, BC has tackled this issue by combining years of sophisticated enterprise technology with the innovation of blockchain. BlockStrain Technology Corporation has developed the first, fully integrated blockchain platform that brings product testing, visibility and integrity to the cannabis industry to bring actionable and real-time quality assurance. BlockStrain is here to use big data to make assurances that customers are protected and to assure the quality and safety of the product.
"Fortunately, BlockStrain accomplishes this by combining the power of genetics with decentralized ledger technology for DNA-based product integrity, verification and tracking. Now, for the first time, consumers can actually know that what they are purchasing is safe, clean and from a legal source. Additionally, although this software is being designed to support the evolving cannabis industry, it could also work to ensure that the organic food industry is also safe and fair-trade. We believe this is a pretty good marriage between science and technology," says Robert Galarza, CEO of BlockStrain.
Mr. Galarza recently announced the addition of Derek Pedro to BlockStrain's Advisory Board. Mr. Pedro was a co-founder and Master Grower at Maricann Group Inc., an early Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR), and is currently the Design, Cultivation and Production Partner at WeedMD Inc., where he designed and supervised construction of that company's production facility in Ontario. "Having Pedro's deep expertise on this board is critical as the company develops its software for use in the evolving legal cannabis industry in Canada,” says Galarza, adding, "He is both a pioneer and a legend in this industry and his knowledge of strain genetics and production systems is incredibly beneficial to BlockStrain as the company builds and adapts its platform for Licensed Producers and other industry stakeholders in Canada.”
Profound Answers May Lie Beyond Human Awareness
Los Angeles, CA, October 30, 2018 — In his deeply insightful writings, Dr. Pieter Noomen shares what he discovered through transcendent experiences during which he fully connected with the source of all existence — something he asserts can be achieved by every human being who is willing to open his or her mind to the information from the universe.
Over the course of many years, Noomen was granted transformative "visits” into another human dimension — on the spirit level — and he freely shares the universal and eternal facts of life that were communicated to him on his website, www.wordsforall.org.
As he explains on his website, "I can only say that the information came from a presence on my innermost spiritual level I was in communication with for some time. The words seem the result of my spirit merging with the spirit of life It/Her/Himself.”
Visitors to Noomen's website can read about the 12 components of life through his 12 booklets: Oneness, Love, Life, Fire, Space, Connectedness, Progression, Effect, Freedom, Joy, Differentness and Harmony. Throughout his writings, Noomen avoids using the name of any deity, such as God, and instead uses what he refers to as The Seven Names, each of which relates on a human level to the situation at hand: One Holy, Love, Truth, Proper, Healing, Manifestation and Energy.
A series of lessons on the site shares 147 thought-provoking questions and the illuminating answers that came to him during his extensive communications with the All Spirit.
Ultimately, Noomen posits that directly or indirectly, life stems from one common source and that to connect with that source is the highest level of existence we can achieve on earth.
"In death,” Noomen writes, "everyone will, without exception and in a purely personal way, find out whether or not there is another dimension of existence.” The reflections shared on Noomen's website invite readers to not wait until the end of their earthly lives for the answer.
Born in the Netherlands, Pieter Noomen completed doctoral studies in theology and pastoral psychology at the Free University of Amsterdam and was senior minister of three protestant churches. Later he worked as a psychotherapist and as a staff member of a Los Angeles metropolitan church. He was involved in mental health issues like suicide prevention and hospice. His personal spiritual path widened substantially — unexpectedly and quite sensationally —25 years ago when he was drawn to the insights of Dr. Peter D. Francuch (1934-2001), who wrote about his communications with what he called the Positive State. This led to Noomen's interest in experiencing a direct, personal connection with the One Who is Life. Noomen is retired and resides in Hollywood, California.
To read the works of Dr. Pieter Noomen, please visit www.wordsforall.org.
